Hamideh Parhiz, PharmD, PhD
Assistant Professor of Systems Pharmacology and Translational Therapeutics
Co-director of targeting core, Penn Institute for RNA Innovation,
University of Pennsylvania
Department: Systems Pharmacology and Translational Therapeutics
Contact information
421 Curie Boulevard
Biomedical Research Building II/III Room 1256
University of Pennsylvania Perelman School of Medicine
Philadelphia, PA 19104
Biomedical Research Building II/III Room 1256
University of Pennsylvania Perelman School of Medicine
Philadelphia, PA 19104
Graduate Group Affiliations
Education:
PharmD (Pharmacy)
Mashhad University of Medical Sciences, Iran, 2005.
PhD (Pharmaceutical Biotechnology)
Mashhad University of Medical Sciences, Iran, 2011.
Permanent linkPharmD (Pharmacy)
Mashhad University of Medical Sciences, Iran, 2005.
PhD (Pharmaceutical Biotechnology)
Mashhad University of Medical Sciences, Iran, 2011.
Description of Research Expertise
Nucleic acid-based therapeuticsNano-engineering
Targeted delivery of nanomedicine
mRNA therapeutics
Autoimmunity
Cancer Immunology and Immunotherapy
Research Interests:
Our lab develops novel nucleic acid delivery systems, including a new generation of targeted lipid nanoparticle (tLNP), for in vivo cellular reprogramming. We leverage these systems for mRNA-based therapeutics in a variety of non-vaccine applications such as inherited diseases, acquired or congenital hematopoietic conditions, cancers, fibrosis, and acute inflammatory conditions. We also investigate the mechanisms underlying the enhancement of delivery systems such as the ones related to more favorable pharmacokinetic profile, to apply those principles in designing more effective gene and mRNA therapeutics. Currently, the targeted LNP-mRNA platform we design serves as the foundation for ongoing academic programs and industrial product developments.
Selected Publications
Castruccio Castracani C, Breda L, Papp TE, Guerra A, Radaelli E, Assenmacher CA, Finesso G, Mui BL, Tam YK, Fontana S, Riganti C, Fiorito V, Petrillo S, Tolosano E, Parhiz H, Rivella S.: An erythroid-specific lentiviral vector improves anemia and iron metabolism in a new model of XLSA. Blood 145: 98-113, Jan 2025.Chappell ME, Breda L, Tricoli L, Guerra A, Jarocha D, Castruccio Castracani C, Papp TE, Tanaka N, Hamilton N, Triebwasser MP, Ghiaccio V, Fedorky MT, Gollomp KL, Bochenek V, Roche AM, Everett JK, Cook EJ, Bushman FD, Teawtrakul N, Glentis S, Kattamis A, Mui BL, Tam YK, Weissman D, Abdulmalik O, Parhiz H, Rivella S.: Use of HSC-targeted LNP to generate a mouse model of lethal α-thalassemia and treatment via lentiviral gene therapy. Blood 144: 1633-1645, Oct 2024.
Mukalel AJ, Hamilton AG, Billingsley MM, Li J, Thatte AS, Han X, Safford HC, Padilla MS, Papp T, Parhiz H, Weissman D, Mitchell MJ.: Oxidized mRNA Lipid Nanoparticles for In Situ Chimeric Antigen Receptor Monocyte Engineering. Adv Funct Mater 34: 2312038, Jul 2024.
Nong J, Glassman PM, Shuvaev VV, Reyes-Esteves S, Descamps HC, Kiseleva RY, Papp TE, Alameh MG, Tam YK, Mui BL, Omo-Lamai S, Zamora ME, Shuvaeva T, Arguiri E, Gong X, Brysgel TV, Tan AW, Woolfork AG, Weljie A, Thaiss CA, Myerson JW, Weissman D, Kasner SE, Parhiz H, Muzykantov VR, Brenner JS, Marcos-Contreras OA.: Targeting lipid nanoparticles to the blood-brain barrier to ameliorate acute ischemic stroke. Mol Ther 32: 1344-1358, May 2024.
Omo-Lamai S, Wang Y, Patel MN, Essien EO, Shen M, Majumdar A, Espy C, Wu J, Channer B, Tobin M, Murali S, Papp TE, Maheshwari R, Wang L, Chase LS, Zamora ME, Arral ML, Marcos-Contreras OA, Myerson JW, Hunter CA, Tsourkas A, Muzykantov V, Brodsky I, Shin S, Whitehead KA, Gaskill P, Discher D, Parhiz H, Brenner JS.: Lipid Nanoparticle-Associated Inflammation is Triggered by Sensing of Endosomal Damage: Engineering Endosomal Escape Without Side Effects. bioRxiv Apr 2024.
Tilsed CM, Sadiq BA, Papp TE, Areesawangkit P, Kimura K, Noguera-Ortega E, Scholler J, Cerda N, Aghajanian H, Bot A, Mui B, Tam Y, Weissman D, June CH, Albelda SM, Parhiz H.: IL7 increases targeted lipid nanoparticle-mediated mRNA expression in T cells in vitro and in vivo by enhancing T cell protein translation. Proc Natl Acad Sci U S A 121: e2319856121, Mar 2024.
Parhiz H, Atochina-Vasserman EN, Weissman D.: mRNA-based therapeutics: looking beyond COVID-19 vaccines. Lancet 403: 1192-1204, Mar 2024.
Parhiz H, Shuvaev VV, Li Q, Papp TE, Akyianu AA, Shi R, Yadegari A, Shahnawaz H, Semple SC, Mui BL, Weissman D, Muzykantov VR, Glassman PM.: Physiologically based modeling of LNP-mediated delivery of mRNA in the vascular system. Mol Ther Nucleic Acids 35: 102175, Mar 2024.
Billingsley MM, Gong N, Mukalel AJ, Thatte AS, El-Mayta R, Patel SK, Metzloff AE, Swingle KL, Han X, Xue L, Hamilton AG, Safford HC, Alameh MG, Papp TE, Parhiz H, Weissman D, Mitchell MJ.: In Vivo mRNA CAR T Cell Engineering via Targeted Ionizable Lipid Nanoparticles with Extrahepatic Tropism. Small 2024.
Guerra A, Parhiz H, Rivella S.: Novel potential therapeutics to modify iron metabolism and red cell synthesis in diseases associated with defective erythropoiesis. Haematologica 108: 2582-2593, Oct 2023.